To describe the utilization and outcomes of single-agent PD-1/PD-L1 in previously untreated advanced renal cell carcinoma patients
Latest Information Update: 18 Jun 2020
At a glance
- Drugs Avelumab (Primary) ; Nivolumab (Primary) ; Pembrolizumab (Primary)
- Indications Renal cell carcinoma
- Focus Adverse reactions; Therapeutic Use
Most Recent Events
- 18 Jun 2020 New trial record
- 31 May 2020 Results presented at the 56th Annual Meeting of the American Society of Clinical Oncology